BRENUS-PHARMA
13.6.2024 18:31:27 CEST | Business Wire | Press release
Brenus Pharma, French biotech developing its proprietary discovery platform: “Stimulated-Tumor-Cell” (STC), has presented the study design of “BreAK-CRC” First-in-human of STC-1010, Brenus’ lead candidate, during ASCO annual meeting (31st May – 4th June 2024) - Trials in Progress poster session, in Chicago.
Poster here. | Benoit You et al. Journal of Clinical Oncology 42, TPS3635-TPS3635(2024). DOI:10.1200/JCO.2024.42.16_suppl.TPS3635
Authors information’s: here.
Based on STC-1010’ robust preclinical package in vivo, in ovo, ex vivo, BreAK-CRC study will be launched in 9 oncology early phase centers (EU, US) with expert investigators in immunotherapy:
“Cancer vaccines continue to show promising clinical results in solid tumors. STC-1010, is a new immunotherapeutic approach based on cancer vaccine mechanism of action for colorectal cancer patients. In that, “BreAK-CRC” Study is eagerly expected. CRC is still challenging as current immunotherapies were found only active in dMMR/MSI-H “hot” CRC. For the pMMR/MSS population, representing 95% of patients with CRC, there is an important medical need for drugs likely to heat up “cold” tumors and have a real impact for the patient.” François Ghiringhelli (M.D,PhD) Director of early clinical unit CLIPP2 and BreAK-CRC study coordinator, Centre Georges-François Leclerc, University of Burgundy, Dijon, France.
BreAK-CRC trial protocol has been reviewed in pre-submission meeting with the French National Health Authority. The submission of the CTA through the clinical trial information system of the European union is ongoing.
The Phase I/IIA clinical trial, aims to evaluate the safety and efficacy of STC-1010 in patients with unresectable advanced or metastatic colorectal cancer, 2nd cause of cancer mortality worldwide.
The Phase I will assess the tolerability of two dose levels of STC-1010, combined with low-dose immunostimulants and standard of care chemotherapy (SoC). The Phase IIA will enroll patients to further evaluate the treatment's efficacy, particularly focusing on 12-month non-progression rate.
Exploratory analysis will evaluate the immune response and the ctDNA dynamic.
About Brenus Pharma:
Brenus Pharma developing a pioneering discovery platform, Stimulated-Tumor-Cell (STC), leading the way of a new generation of active immunotherapies against cancer.
STC Platform mimics patients' relapsing conditions in vitro to educate the patient’s immune system against tumor evolution and mechanisms of relapse. The STCs will educate the immune system to 200+ specific targets of interest, validated by multi-omics analysis and patient biopsies databases.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240613547215/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
High Awareness, Low Adoption: New Survey Reveals Nearly Half of Security Professionals Still Rely on Passwords7.10.2026 09:01:00 CEST | Press release
Global study from Yubico and Okta highlights a critical execution gap in enterprise security, shows how modern identity controls can eliminate password dependency. A new survey from Yubico (NASDAQ STOCKHOLM: YUBICO), the pioneer of phishing-resistant authentication and creator of the original passkey, the YubiKey, and Okta, Inc., reveals a significant gap between security knowledge and everyday practice. While security leaders overwhelmingly recognize phishing-resistant passkeys as more secure than passwords, nearly half still rely on vulnerable login methods in their daily work. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261007969823/en/ Conducted by Talker Research, the annual 2026 Global State of Authentication* report surveyed nearly 2,000 cybersecurity and IT professionals across nine countries. The report highlights that cybersecurity's primary vulnerability is no longer a lack of education or awareness, but a stru
Wolters Kluwer brings AI-powered drafting directly into the Libra legal workspace7.10.2026 09:01:00 CEST | Press release
In addition to Libra’s existing Word Add-in, Drafting in Libra gives customers the flexibility to choose the drafting environment that best suits their workflow, while automatically applying their firm’s existing templates Wolters Kluwer Legal & Regulatory today announced the launch of Drafting, a major new capability within Libra by Wolters Kluwer, the company’s legal AI workspace. Drafting enables legal professionals to create, edit, review, and collaborate on Word documents directly within the workspace, reducing the need to switch between separate applications throughout the drafting process. Together with Libra's existing Word Add-in, which is already widely used by legal professionals today, the new capability provides customers with a second, fully integrated way to draft their documents. Depending on their preferences and workflow, they can either remain within the Microsoft Word environment or work end-to-end in the Libra legal AI workspace. At the core of Drafting is the Libr
ClaroNav Kolahi Inc. Announces EU MDR Certification for Navient Surgical Navigation System7.10.2026 09:00:00 CEST | Press release
ClaroNav Kolahi Inc. (CKI), a global developer and manufacturer of surgical navigation technologies, today announced that its Navient Surgical Navigation System has received certification under the European Union Medical Device Regulation, EU MDR. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261007890668/en/ ClaroNav Kolahi Inc. Announces EU MDR Certification for Navient Surgical Navigation System The certification covers the Navient Image Guided Navigation System and its reusable surgical instruments, allowing CKI to continue offering Navient throughout the European Union under the EU MDR regulatory framework. “EU MDR certification is an important milestone for CKI and demonstrates our continued commitment to meeting the highest standards for safety, quality, and regulatory compliance,” said Ahmad Kolahi, CEO of CKI. Navient was previously certified under EU MDD and has received regulatory approvals including US FDA, Heal
Yapı Kredi Kripto Selects Integral to Power Digital Asset Trading Services in Türkiye7.10.2026 09:00:00 CEST | Press release
Integral's institutional-grade digital asset trading technology will support Yapı Kredi Kripto's regulated cryptocurrency offering as Türkiye's new digital asset framework comes into effect. Integral, a leading provider of currency technology, today announced that Yapı Kredi Kripto has selected Integral's digital asset trading technology, enabling the group to provide cryptocurrency services through its soon-to-launch regulated digital asset business. The partnership comes as Türkiye introduces a new regulatory framework for digital asset service providers, creating a regulated environment for financial institutions to expand their offering to customers seeking access to cryptocurrency markets. Yapı Kredi Kripto has implemented Integral's digital asset trading technology across pricing, liquidity and risk management, providing the infrastructure required to deliver a secure and efficient cryptocurrency trading experience to its customers. Integral's established presence in Türkiye was
CRH to Acquire Aggregate Operations in Denmark and Finland7.10.2026 08:24:00 CEST | Press release
Transaction Advances CRH’s Strategy to Build Aggregates-led, Connected Portfolio Aligned With Growing Infrastructure Megatrends CRH (NYSE: CRH), the leading provider of building materials, today announced that it has signed an agreement to acquire NCC Industry’s operations in Denmark and Finland from NCC AB. NCC Industry develops, produces and sells stone materials and asphalt products for construction and infrastructure projects. In Denmark NCC Industry’s national network of asphalt plants, land and marine based aggregates sites, together with its substantial high-quality reserves, will significantly expand CRH's presence in the market and its exposure to demand from major road, infrastructure and industrial projects. While in Finland NCC Industry’s attractive network of reserve backed hard-rock quarries, backfilling and recycling operations will complement CRH’s existing operations and connected portfolio of businesses in the Finnish market. Peter Buckley, President, CRH Internationa
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom